Cogent Biosciences (NASDAQ: COGT) experienced a 120% surge in premarket trading on November 10, 2025, after announcing positive results from its Phase 3 trial for bezuclastinib, a treatment for gastrointestinal stromal tumors (GIST). The trial demonstrated that bezuclastinib, when combined with sunitinib, significantly reduced the risk of disease progression or death by 50% compared to sunitinib alone. Following these promising results, Cogent Biosciences plans to submit a New Drug Application in 2026. The drug has also been granted FDA Breakthrough Therapy Designation, highlighting its potential to address unmet medical needs in GIST treatment.